Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland

• Published in: Asian Pacific journal of cancer prevention : APJCP 2015, Vol.16 (9), p.4013-4018
• Main Authors: Zhu, Qiang, Zang, Qi, Jiang, Zhong-Min, Wang, Wei, Cao, Ming, Su, Gong-Zhang, Zhen, Tian-Chang, Zhang, Xiao-Tian, Sun, Ning-Bo, Zhao, Cheng
• Format: Article
• Language: Korean
• ISSN: 1513-7368; 2476-762X

Objective: To explore the clinical application of recombinant human endostatin (Endostar) in the treatment of patients with non-small cell lung cancer (NSCLC) in Chinese mainland. Materials and Methods: A total of 75 patients diagnosed as NSCLC were randomly divided into control group (37 cases) and treatment group (38 cases). Control group was treated with postoperative complementary chemotherapy containing two-agent platinum protocol on postoperative d21, 3 weeks as a cycle, for totally 4~6 cycles. On this basis, treatment group was added with Endostar $7.5mg/m^2$ on postoperative d8~9, 3~4 h/time, qd, 14 weeks as a cycle, for totally 4 cycles. The interval between every two cycles was 7 d. The 5-year progression-free survival (PFS), 5-year survival time and complications in both groups were observed. Results: Compared with control group, the average PFS increased evidently in treatment group by 9.8 months (41.6 months vs. 31.8 months), and there was significant difference (P